Skip to main content
. 2021 Jan 22;100(3):e23423. doi: 10.1097/MD.0000000000023423

Figure 5.

Figure 5

LncRNA NEAT1 competes with FGF9 for binding to miR-365. Note: (A) The wild and mutated sequences of the binding sites of NEAT1 and FGF9 to miR-365; dual-luciferase reporter assay tested (B) the binding of NEAT1 to miR-365, and (C) the binding of FGF9 to miR-365. ∗P < .05, compared to mimic NC group. (D) qRT-PCR detected the expression of miR-365 in OC cells transfected with sh-NEAT1 or pcDNA3.1-NEAT1. (E) qRT-PCR measured the expression of miR-365 in SKOV3 cells, OVCAR-3 cells and IOSE80 cells. ∗P < .05, compared to IOSE80 group. After SKOV3 cells and OVCAR-3 cells were transfected with miR-365 mimic or miR-365 inhibitor, (F) qRT-PCR detected the expression of miR-365; (G) CCK8 tested cell proliferation activity; (H) clone formation assay measured the number of colonies; (I) Matrigel angiogenesis assay tested the number of vascular branches formed by HUEVCs; (J) qRT-PCR and (K) Western blot analyzed the expressions of VEGF, Ang-1 and MMP2 in HUEVCs. ∗P < .05, ∗∗P < .01, compared to mimic NC group or sh-NC group; #P < .05, ##P < .01, compared to inhibitor NC group or pcDNA3.1 group; qRT-PCR, quantitative reverse transcript polymerase chain reaction; HUEVCs, human umbilical vein endothelial cells.